This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary c-Met/HGFR Therapeutic Antibody Development
c-Met/HGFR has become one of the hot research targets in the field of cancer, and the development of its antibodies holds potential therapeutic significance for companion animals suffering from targeted diseases. BioVenic offers services in the development of veterinary c-Met/HGFR therapeutic antibodies, dedicated to assisting in advancing companion animal healthcare. We have established a multi-type platform for the development of veterinary therapeutic antibodies, utilizing emerging technologies for antibody preparation and optimization, to provide you with a high-quality experience.
Background of c-Met/HGFR
| Full Name | c-Mesenchymal-epithelial transition factor/Hepatocyte growth factor receptor |
|---|---|
| Aliases | AUTS9, DA11, DFNB97, MET, RCCP2. |
| Target Profile | As a tyrosine kinase receptor, c-Met/HGFR consists of three structural domains: an extracellular region, a transmembrane domain, and an intracellular region. It is primarily expressed on the cell surface, and its ligand is hepatocyte growth factor (HGF), playing a crucial role in both normal tissue development and tumor progression. |
MoA of c-Met/HGFR
The primary ligand for c-Met is the hepatocyte growth factor (HGF). HGF, a member of the soluble cytokine family, activates the HGF/c-Met signaling through a paracrine mechanism, subsequently triggering a series of downstream signaling pathways such as RAS/MAPK and PI3K/AKT to exert its biological functions. Under normal physiological conditions, the binding of HGF to c-Met can induce tyrosine phosphorylation, promoting cell proliferation, growth, migration, differentiation, and tissue repair effects. When the regulation of the c-Met pathway is abnormal, such as through overexpression, it may initiate the transformation of normal cells into tumor cells, promote tumor cell proliferation and metastasis, and further drive their invasion, metastasis, and spread.
Fig.1 Schematic diagram of HGF/c-Met pathways.1
Application in Veterinary Therapeutics
c-Met/HGFR can play a significant role in the treatment of tumors in companion animals. The increase in c-Met/HGFR is a negative prognostic factor, as it can lead to an increase in the malignancy of tumors. For canine mammary tumors, c-Met/HGFR exhibits complex overexpression and dysregulation. Therefore, c-Met/HGFR can be a potential target for the treatment of canine mammary tumors. The development of veterinary c-Met/HGFR therapeutic antibodies aimed at inhibiting its overexpression can reduce its impact on tumor cell proliferation and metastasis.
Veterinary c-Met/HGFR Therapeutic Antibody Development Services
Numerous cancer treatment research projects focusing on c-Met/HGFR are currently underway. To support research targeting this marker in companion animals such as canines, felines, and equines, Biovenic offers veterinary c-Met/HGFR therapeutic antibody development services. Our services encompass every stage from antibody design and characterization to engineering optimization, fully meeting development needs and ensuring the antibodies are optimally suited for therapeutic research in companion animals.
To learn more about our c-Met/HGFR therapeutic antibody development services, please click the link below.
Why Choose Us?
A wide range of veterinary therapeutic antibody development technologies is available for your selection.
We offer antibody characterization services to ensure the quality of veterinary therapeutic antibodies, including sterility testing and purity analysis as part of our quality control measures.
We provide species-specific antibody development services, while also maintaining high antibody affinity to ensure therapeutic effectiveness.
Dysregulation in the c-Met/HGFR pathway in oncology can be manifested through genetic mutations, amplification, rearrangement, or overexpression of proteins. Blocking the HGF/c-Met signaling pathway may effectively inhibit the occurrence, progression, and metastasis of tumors. BioVenic offers veterinary c-Met/HGFR therapeutic antibody development services to assist you in exploring tumor treatments in companion animals such as canine, feline, and equine. If you have needs in this area, please do not hesitate to contact us now.
References
- Tian, Zhennan, et al. "IGF2R expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC." Cellular Physiology and Biochemistry 34.5 (2014): 1578-1588.
- Koltai, Zsófia, et al. "Tyrosine kinase expression analyses in canine mammary gland tumours–A pilot study." Acta Veterinaria Hungarica 66.2 (2018): 294-308.